Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

This trial is testing a new drug called ZG006 — an antibody-drug conjugate (a targeted therapy that delivers a cancer-killing agent directly to tumor cells) — for people with advanced small cell lung cancer (SCLC) or neuroendocrine carcinoma. SCLC is an aggressive form of lung cancer, and neuroendocrine carcinomas are tumors arising from hormone-producing cells. **You may be eligible if...** - You are between 18 and 75 years old - You are in good physical condition (ECOG 0-1) with a life expectancy of at least 3 months - You have been diagnosed with advanced small cell lung cancer OR neuroendocrine carcinoma (in the first dose-finding phase) - For the dose-expansion phase: you have advanced SCLC, either de-novo (never transformed) and on third-line or later, or transformed SCLC, or large-cell neuroendocrine carcinoma **You may NOT be eligible if...** - You have significant medical conditions that the investigator feels make participation unsafe - You do not meet the specific disease subtype requirements for your cohort Talk to your doctor to see if this trial is right for you.